How to buy TFF Pharmaceuticals stock

TFF Pharmaceuticals, Inc is a biotechnology business based in the US. TFF Pharmaceuticals shares (TFFP) are listed on the NASDAQ and all prices are listed in US Dollars. TFF Pharmaceuticals employs 4 staff and has a market cap (total outstanding shares value) of 0.00.

TFF Pharmaceuticals share price

Use our graph to track the performance of TFFP stocks over time.

TFF Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$4.31 - $21.14
50-day moving average	$14.04
200-day moving average	$15.43
Wall St. target price	$31.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.00

Buy TFF Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy TFF Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of TFF Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

TFF Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-34.44%
Return on equity TTM	-57.14%
Profit margin	0%
Book value	N/A
Market capitalisation	$291.4 million

TTM: trailing 12 months

Shorting TFF Pharmaceuticals shares

There are currently 438,531 TFF Pharmaceuticals shares held short by investors – that's known as TFF Pharmaceuticals's "short interest". This figure is 43.6% up from 305,330 last month.

There are a few different ways that this level of interest in shorting TFF Pharmaceuticals shares can be evaluated.

TFF Pharmaceuticals's "short interest ratio" (SIR)

TFF Pharmaceuticals's "short interest ratio" (SIR) is the quantity of TFF Pharmaceuticals shares currently shorted divided by the average quantity of TFF Pharmaceuticals shares traded daily (recently around 425758.25242718). TFF Pharmaceuticals's SIR currently stands at 1.03. In other words for every 100,000 TFF Pharmaceuticals shares traded daily on the market, roughly 1030 shares are currently held short.

However TFF Pharmaceuticals's short interest can also be evaluated against the total number of TFF Pharmaceuticals shares, or, against the total number of tradable TFF Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TFF Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 TFF Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0221% of the tradable shares (for every 100,000 tradable TFF Pharmaceuticals shares, roughly 22 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against TFF Pharmaceuticals.

Find out more about how you can short TFF Pharmaceuticals stock.

TFF Pharmaceuticals share dividends

We're not expecting TFF Pharmaceuticals to pay a dividend over the next 12 months.

TFF Pharmaceuticals overview

TFF Pharmaceuticals, Inc. , an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform in the United States and Australia. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which has completed Phase I clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in the Phase I clinical trials used for the prevention of lung transplant rejection. It is also developing other dry powder products, such as Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various types of pain; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S.

Frequently asked questions

• What percentage of TFF Pharmaceuticals is owned by insiders or institutions?

  Currently 16.312% of TFF Pharmaceuticals shares are held by insiders and 28.124% by institutions.

• How many people work for TFF Pharmaceuticals?

  Latest data suggests 4 work at TFF Pharmaceuticals.

• When does the fiscal year end for TFF Pharmaceuticals?

  TFF Pharmaceuticals's fiscal year ends in December.

• Where is TFF Pharmaceuticals based?

  TFF Pharmaceuticals's address is: 2600 Via Fortuna, Austin, TX, United States, 78746

• What is TFF Pharmaceuticals's ISIN number?

  TFF Pharmaceuticals's international securities identification number is: US87241J1043

• What is TFF Pharmaceuticals's CUSIP number?

  TFF Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 87241J104